Form 4: EcoR1 Capital Increases Stake in Zymeworks Inc. Through Multiple Share Purchases

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of share purchases in late December 2024 and early January 2025.

Summary

• EcoR1 Capital, along with its related entities, has acquired additional shares of Zymeworks Inc. common stock.
• The purchases occurred on December 30, 2024, December 31, 2024, and January 2, 2025.
• A total of 363,369 shares were purchased across the three transactions.
• The weighted average purchase prices ranged from $14.4661 to $14.7796 per share.
• Following these transactions, EcoR1 Capital's total indirect holdings in Zymeworks increased to 15,185,959 shares.
• The shares are held indirectly through EcoR1 Capital Fund Qualified, L.P., a fund managed by EcoR1 Capital, LLC.

Sentiment

Score: 7

Explanation: The document indicates a positive sentiment due to the increased investment by a major shareholder, suggesting confidence in the company's future. However, it is a routine filing and does not contain any major news.

Positives

• The increased share purchases by EcoR1 Capital indicate a strong belief in the future prospects of Zymeworks.
• The consistent buying activity suggests a positive outlook from a major shareholder.

Risks

• The document does not explicitly state any risks, but the increased ownership by a single entity could potentially lead to greater influence over the company's direction.

Management Comments

• The filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.
• The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein.

Industry Context

This filing is a routine disclosure of share transactions by a major shareholder, which is common in the biotech industry. It reflects the ongoing investment activity and confidence of institutional investors in the company.

Comparison to Industry Standards

• Similar filings are common for companies with significant institutional ownership, such as those in the biotechnology sector.
• The share purchases are not unusual in the context of institutional investors adjusting their positions based on their investment strategies and outlook for the company.
• Other biotech companies with similar institutional ownership structures would likely have similar filings when major shareholders adjust their positions.

Stakeholder Impact

• The increased share purchases could positively impact shareholder confidence.
• The transactions do not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Zymeworks, EcoR1 Capital, Share Purchases, Beneficial Ownership, Stock Transactions, Form 4, Investment